3SBio Inc.
1530
Ранг среди акций
#3615
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Цена акции
$1.88
Рыночная капитализация
$4.70B
Изменение (1 день)
1.59%
Изменение (1 год)
-48.02%
Страна
CN
Торговля 3SBio Inc. (1530)
Категория
Healthcare
Операционная маржа для 3SBio Inc. (1530)
Операционная маржа на October 2026 TTM: 61.16%
Согласно последним финансовым отчетам и цене акций 3SBio Inc., текущая операционная маржа (TTM) составляет 61.16%. В конце 2023 она составила 31.45%.
История операционной маржи 3SBio Inc. с 2012 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | 61.16% | 110.32% |
| 2024 | 29.08% | -7.54% |
| 2023 | 31.45% | 4.24% |
| 2022 | 30.17% | 5.42% |
| 2021 | 28.62% | 9.40% |
| 2020 | 26.16% | 4.14% |
| 2019 | 25.12% | -20.25% |
| 2018 | 31.50% | 1.81% |
| 2017 | 30.94% | -4.77% |
| 2016 | 32.49% | 13.56% |
| 2015 | 28.61% | -14.80% |
| 2014 | 33.58% | 5.46% |
| 2013 | 31.84% | 57.08% |
| 2012 | 20.27% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 38.59% | -99.37% |
US
|
|
| -149.01% | -102.44% |
US
|
|
| 25.57% | -99.58% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.53% |
NL
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.